Pharma        CDMO Services

News

Our milestones and achievements in the press

21/01/2026
ESTEVE BECOMES A B CORP COMPANY FOR ITS SOCIAL COMMITMENT, ENVIRONMENTAL AWARENESS, AND TRANSPARENCY
13/01/2026
ESTEVE TO ACQUIRE TERSERA THERAPEUTICS’ INFUSION SPECIALTY THERAPIES BUSINESS UNIT, EXPANDING U.S. PRESENCE
04/11/2025
MAR HERNÁNDEZ JOINS ESTEVE AS CHIEF PEOPLE & ORGANIZATION OFFICER
31/07/2025
ESTEVE ACQUIRES REGIS TECHNOLOGIES, EXPANDING U.S. PRESENCE AND CAPABILITIES
30/06/2025
ESTEVE TO ACQUIRE MEDICINE TO TREAT MEDULLARY THYROID CANCER
14/05/2025
ESTEVE INCREASES NET REVENUE BY 5% AND REAFFIRMS STRATEGY TOWARDS BECOMING A HIGHLY SPECIALIZED COMPANY
01/04/2025
ESTEVE SIGNS A LICENSING AGREEMENT FOR A SEVERE PRIMARY INSULIN-LIKE GROWTH FACTOR 1 DEFICIENCY TREATMENT
10/07/2024
ESTEVE ACQUIRES HRA PHARMA RARE DISEASES
28/06/2024
ESTEVE WILL INVEST 100 MILLION EUROS IN THE CONSTRUCTION OF A NEW PLANT AT ITS INDUSTRIAL CENTRE IN CELRÀ (GIRONA)
16/05/2024
ESTEVE CONSOLIDATES ITS DOUBLE-DIGIT GROWTH AND REACHES €710 MILLION IN NET REVENUE
25/04/2024
ESTEVE SIGNS A BINDING OFFER TO ACQUIRE HRA PHARMA RARE DISEASES, A PERRIGO COMPANY AFFILIATE
08/04/2024
JACOB TOLSTRUP, JOINS ESTEVE AS CHIEF BUSINESS DEVELOPMENT OFFICER
29/02/2024
ESTEVE RENEWS ITS BOARD OF DIRECTORS TO CONTINUE DRIVING STRATEGIC GROWTH
03/10/2023
ROSER GOMILA, JOINS ESTEVE AS CHIEF FINANCIAL OFFICER
17/05/2023
ESTEVE REPORTS SIGNIFICANT GROWTH IN 2022 AND CONTINUES TO ADVANCE TOWARDS ITS VISION OF BECOMING AN INTERNATIONAL SPECIALTY PHARMA COMPANY
07/03/2023
ESTEVE BRINGS TO MARKET THE FIRST INHALED RESCUE TREATMENT DESIGNED TO CONTROL OFF EPISODES IN PARKINSON’S DISEASE¹
23/11/2022
ESTEVE AND MEDTRONIC ARE COLLABORATING TO ADDRESS CANCER PAIN PATIENTS’ NEEDS
03/11/2022
PERE ARAGONÉS, PRESIDENT OF THE GOVERNMENT OF CATALONIA, VISITS ESTEVE’S MAIN INDUSTRIAL PLANT
26/05/2022
ESTEVE REINFORCES ITS COMMITMENT TO SUSTAINABILITY IN ALL THREE DIMENSIONS: SOCIAL, ENVIRONMENTAL AND ECONOMIC
27/04/2022
ESTEVE ENTERS IN THE PORTUGUESE OPHTHALMOLOGY MARKET
08/04/2022
INTRAPHARM BECOMES ESTEVE UK
07/03/2022
ESTEVE AND FEP JOIN FORCES TO RAISE AWARENESS OF PARKINSON’S DISEASE
07/02/2022
ESTEVE APPOINTS JOSÉ MARÍA GIMÉNEZ ARNAU AS CHIEF SCIENTIFIC & MEDICAL OFFICER
01/02/2022
ESTEVE INCREASES ITS PRODUCTION CAPACITY IN SPAIN
16/11/2021
RIEMSER BECOMES ESTEVE GERMANY WITH A NEW MANAGING DIRECTOR, KLAUS SCHWARZ
18/10/2021
ESTEVE ANNOUNCES FDA APPROVAL OF A NOVEL CO-CRYSTAL FORM OF CELECOXIB AND TRAMADOL FOR THE MANAGEMENT OF ACUTE PAIN
14/10/2021
FOLLOWING IN THE WAKE OF COVID-19, MYOPIA WILL BE THE NEXT PANDEMIC TO EMERGE, ESPECIALLY AMONG CHILDREN AND YOUNG PEOPLE
20/07/2021
ESTEVE QUIMICA ANNOUNCES AGREEMENT WITH SEAGEN TO PRODUCE TUCATINIB (TUKYSA®)
03/06/2021
BY 2023, 100% OF ESTEVE’S COMMERCIAL FLEET WILL BE PLUG-IN HYBRID AND ELECTRIC CARS
03/05/2021
ESTEVE AND KOWA PHARMACEUTICALS AMERICA ENTER INTO AN EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT FOR RIGHTS TO E-58425 FOR THE POTENTIAL MANAGEMENT OF ACUTE PAIN1-9 IN THE UNITED STATES8,9
30/04/2021
PROFARMA HAS ONCE AGAIN RATED ESTEVE’S RESEARCH AND INNOVATION ACTIVITY AS "EXCELLENT"
12/02/2021
ESTEVE IS COLLABORATING IN A CLINICAL TRIAL ON EARLY TREATMENT OF PATIENTS WITH MILD COVID-19 SYMPTOMS AND CONFIRMED INFECTION